First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
Clinical Questions Addressed by the Comparative Effectiveness Review (2 of 2)
The comparative effectiveness review focused on the first-generation (FGAs) and second-generation (SGAs) antipsychotics used to treat adults (ages 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, and bipolar disorder (all are approved indications). Clinical questions addressed by the comparative effectiveness review include:
- Do FGAs and SGAs differ in medication-associated adverse effects and safety?
- What is the comparative effectiveness of FGAs versus SGAs for outcomes other than core illness symptoms, such as relapse and remission rates, medication adherence, patient insight, health-related quality of life, and patient satisfaction?
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC054-EF. Available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm.
Your slide tray is being processed.